Guard Therapeutics International AB (publ) (GUARD.ST)
SEK 18.8
(2.73%)
SEK 18.8
(2.73%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 18.49 Million SEK | -26.74% |
| 2022 | 25.24 Million SEK | 72.2% |
| 2021 | 14.66 Million SEK | 27.08% |
| 2020 | 11.53 Million SEK | 4.02% |
| 2019 | 11.09 Million SEK | -63.3% |
| 2018 | 30.21 Million SEK | 158.65% |
| 2017 | 11.68 Million SEK | -3.71% |
| 2016 | 12.13 Million SEK | 34.74% |
| 2015 | 9 Million SEK | 57.61% |
| 2014 | 5.71 Million SEK | -73.74% |
| 2013 | 21.75 Million SEK | 26.15% |
| 2012 | 17.24 Million SEK | 204.79% |
| 2011 | 5.65 Million SEK | 549.0% |
| 2010 | 871.81 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 18.09 Million SEK | 33.18% |
| 2024 Q1 | 13.58 Million SEK | -26.53% |
| 2023 Q1 | 29.67 Million SEK | 17.54% |
| 2023 Q4 | 18.49 Million SEK | -14.57% |
| 2023 FY | 18.49 Million SEK | -26.74% |
| 2023 Q3 | 21.64 Million SEK | -11.87% |
| 2023 Q2 | 24.56 Million SEK | -17.22% |
| 2022 Q3 | 19.36 Million SEK | 15.87% |
| 2022 FY | 25.24 Million SEK | 72.2% |
| 2022 Q2 | 16.71 Million SEK | 6.22% |
| 2022 Q4 | 25.24 Million SEK | 30.33% |
| 2022 Q1 | 15.73 Million SEK | 7.35% |
| 2021 FY | 14.66 Million SEK | 27.08% |
| 2021 Q1 | 15.21 Million SEK | 31.87% |
| 2021 Q4 | 14.66 Million SEK | -10.41% |
| 2021 Q3 | 16.36 Million SEK | 28.86% |
| 2021 Q2 | 12.69 Million SEK | -16.53% |
| 2020 Q4 | 11.53 Million SEK | -17.52% |
| 2020 FY | 11.53 Million SEK | 4.02% |
| 2020 Q2 | 12.87 Million SEK | -11.74% |
| 2020 Q3 | 13.98 Million SEK | 8.62% |
| 2020 Q1 | 14.58 Million SEK | 31.55% |
| 2019 Q1 | 17.14 Million SEK | -43.26% |
| 2019 Q4 | 11.09 Million SEK | 3.18% |
| 2019 Q3 | 10.74 Million SEK | -34.78% |
| 2019 FY | 11.09 Million SEK | -63.3% |
| 2019 Q2 | 16.48 Million SEK | -3.88% |
| 2018 Q1 | 21.72 Million SEK | 85.96% |
| 2018 FY | 30.21 Million SEK | 158.65% |
| 2018 Q4 | 30.21 Million SEK | 174.51% |
| 2018 Q3 | 11 Million SEK | 10.09% |
| 2018 Q2 | 9.99 Million SEK | -53.98% |
| 2017 Q2 | 6.53 Million SEK | -72.99% |
| 2017 Q4 | 11.68 Million SEK | 28.15% |
| 2017 FY | 11.68 Million SEK | -3.71% |
| 2017 Q3 | 9.11 Million SEK | 39.5% |
| 2017 Q1 | 24.19 Million SEK | 99.44% |
| 2016 Q3 | 10.58 Million SEK | 26.24% |
| 2016 Q2 | 8.38 Million SEK | 26.46% |
| 2016 Q1 | 6.63 Million SEK | -26.33% |
| 2016 FY | 12.13 Million SEK | 34.74% |
| 2016 Q4 | 12.13 Million SEK | 14.57% |
| 2015 FY | 9 Million SEK | 57.61% |
| 2015 Q2 | 8.87 Million SEK | -11.41% |
| 2015 Q4 | 9 Million SEK | 58.74% |
| 2015 Q3 | 5.67 Million SEK | -36.1% |
| 2015 Q1 | 10.01 Million SEK | 75.37% |
| 2014 Q1 | 23.44 Million SEK | 7.79% |
| 2014 Q4 | 5.71 Million SEK | -12.01% |
| 2014 FY | 5.71 Million SEK | -73.74% |
| 2014 Q3 | 6.49 Million SEK | 10.95% |
| 2014 Q2 | 5.85 Million SEK | -75.04% |
| 2013 Q2 | 17.78 Million SEK | 101592.88% |
| 2013 Q1 | 17.48 Thousand SEK | -99.9% |
| 2013 Q3 | 17.16 Million SEK | -3.48% |
| 2013 Q4 | 21.75 Million SEK | 26.76% |
| 2013 FY | 21.75 Million SEK | 26.15% |
| 2012 FY | 17.24 Million SEK | 204.79% |
| 2012 Q4 | 17.24 Million SEK | 0.0% |
| 2011 FY | 5.65 Million SEK | 549.0% |
| 2010 FY | 871.81 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 82.65% |
| Ziccum AB (publ) | 6.38 Million SEK | -189.512% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -683.976% |
| BioArctic AB (publ) | 139.5 Million SEK | 86.743% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 46.554% |
| Mendus AB (publ) | 51.22 Million SEK | 63.897% |
| Genovis AB (publ.) | 98.04 Million SEK | 81.138% |
| Intervacc AB (publ) | 21.68 Million SEK | 14.696% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 30.755% |
| Active Biotech AB (publ) | 13.4 Million SEK | -38.015% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 85.083% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -14.748% |
| Aptahem AB (publ) | 8.99 Million SEK | -105.539% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 54.737% |
| Kancera AB (publ) | 17.97 Million SEK | -2.87% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 59.952% |
| Fluicell AB (publ) | 8.91 Million SEK | -107.448% |
| Saniona AB (publ) | 86.08 Million SEK | 78.516% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -258.55% |
| Biovica International AB (publ) | 34.76 Million SEK | 46.806% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -58.502% |
| AcouSort AB (publ) | 10.37 Million SEK | -78.204% |
| Xintela AB (publ) | 14.01 Million SEK | -31.959% |
| Abliva AB (publ) | 16.78 Million SEK | -10.208% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 91.382% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -59.858% |
| OncoZenge AB (publ) | 1.69 Million SEK | -988.523% |
| Amniotics AB (publ) | 10.54 Million SEK | -75.348% |
| 2cureX AB (publ) | 2.93 Million SEK | -530.119% |
| CombiGene AB (publ) | 4.15 Million SEK | -344.995% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -317.849% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 98.819% |
| Camurus AB (publ) | 414.81 Million SEK | 95.542% |
| Corline Biomedical AB | 6.78 Million SEK | -172.411% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 69.858% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 3.496% |
| I-Tech AB | 16.2 Million SEK | -14.125% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.441% |
| Cyxone AB (publ) | 4.69 Million SEK | -293.992% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -38.761% |
| Biosergen AB | 5.08 Million SEK | -263.697% |
| Cantargia AB (publ) | 54.97 Million SEK | 66.356% |
| NextCell Pharma AB | 13.68 Million SEK | -35.101% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 74.26% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -34.291% |
| Nanologica AB (publ) | 79.32 Million SEK | 76.686% |
| SynAct Pharma AB | 51.83 Million SEK | 64.321% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -132.658% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -256.0% |
| LIDDS AB (publ) | 3.75 Million SEK | -392.386% |
| Lipum AB (publ) | 7.53 Million SEK | -145.344% |
| BioInvent International AB (publ) | 90.45 Million SEK | 79.554% |
| Alzinova AB (publ) | 9.33 Million SEK | -98.2% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 89.816% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -930.881% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -381.866% |
| Simris Alg AB (publ) | 148.93 Million SEK | 87.583% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 73.995% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 96.164% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -45.119% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -154.738% |